Skip to main content Accessibility help
×
Home
Hostname: page-component-56f9d74cfd-mtzzk Total loading time: 0.779 Render date: 2022-06-25T23:05:29.904Z Has data issue: true Feature Flags: { "shouldUseShareProductTool": true, "shouldUseHypothesis": true, "isUnsiloEnabled": true, "useRatesEcommerce": false, "useNewApi": true }

Book contents

4 - Tracking Oral Antipsychotic Adherence

Published online by Cambridge University Press:  19 October 2021

Jonathan M. Meyer
Affiliation:
University of California, San Diego
Stephen M. Stahl
Affiliation:
University of California, Riverside and San Diego
Get access

Summary

That people with chronic illness do not take all of their oral medications is well established, and schizophrenia is not unique in this regard. A World Health Organization study estimated that medication adherence among patients with chronic diseases averages only 50% in developed countries, with recent data indicating a rate of 45% for hypertension specifically [1, 2]. Unlike hypertension, where the impact of nonadherence might not be felt for years, poor adherence with oral antipsychotic therapy can result in psychotic relapse within days or weeks, leading to hospitalization, social disruption, and legal sequelae (e.g. increased risk for violence) [3, 4].

Type
Chapter
Information
The Clinical Use of Antipsychotic Plasma Levels
Stahl's Handbooks
, pp. 87 - 113
Publisher: Cambridge University Press
Print publication year: 2021

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Lam, W. Y. and Fresco, P. (2015). Medication adherence measures: An overview. Biomed Res Int, 2015, 217047.
Abegaz, T. M., Shehab, A., Gebreyohannes, E. A., et al. (2017). Nonadherence to antihypertensive drugs: A systematic review and meta-analysis. Medicine (Baltimore), 96, e5641.
Buchanan, A., Sint, K., Swanson, J., et al. (2019). Correlates of future violence in people being treated for schizophrenia. Am J Psychiatry, 176, 694701.
Velligan, D. I., Maples, N. J., Pokorny, J. J., et al. (2020). Assessment of adherence to oral antipsychotic medications: What has changed over the past decade? Schizophr Res, 215, 1724.
Takeuchi, H., Siu, C., Remington, G., et al. (2019). Does relapse contribute to treatment resistance? Antipsychotic response in first- vs. second-episode schizophrenia. Neuropsychopharmacology, 44, 10361042.
Kishi, T., Oya, K., and Iwata, N. (2016). Long-acting injectable antipsychotics for the prevention of relapse in patients with recent-onset psychotic disorders: A systematic review and meta-analysis of randomized controlled trials. Psychiatry Res, 246, 750755.
Kishimoto, T., Hagi, K., Nitta, M., et al. (2018). Effectiveness of long-acting injectable vs oral antipsychotics in patients with schizophrenia: A meta-analysis of prospective and retrospective cohort studies. Schizophr Bull, 44, 603619.
Miura, G., Misawa, F., Kawade, Y., et al. (2019). Long-acting injectables versus oral antipsychotics: A retrospective bidirectional mirror-image study. J Clin Psychopharmacol, 39, 441445.
Weiden, P. J., Schooler, N. R., Weedon, J. C., et al. (2009). A randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: Initial adherence outcome. J Clin Psychiatry, 70, 13971406.
Weiden, P. J., Schooler, N. R., Weedon, J. C., et al. (2012). Maintenance treatment with long-acting injectable risperidone in first-episode schizophrenia: A randomized effectiveness study. J Clin Psychiatry, 73, 12241233.
Subotnik, K. L., Casaus, L. R., Ventura, J., et al. (2015). Long-acting injectable risperidone for relapse prevention and control of breakthrough symptoms after a recent first episode of schizophrenia: A randomized clinical trial. JAMA Psychiatry, 72, 822829.
Kane, J. M., Schooler, N. R., Marcy, P., et al. (2019). Patients with early-phase schizophrenia will accept treatment with sustained-release medication (long-acting injectable antipsychotics): Results from the recruitment phase of the PRELAPSE trial. J Clin Psychiatry, 80, 18m12546.
Abdel-Baki, A., Medrano, S., Maranda, C., et al. (2020). Impact of early use of long-acting injectable antipsychotics on psychotic relapses and hospitalizations in first-episode psychosis. Int Clin Psychopharmacol, 35, 221228.
Kane, J. M., Schooler, N. R., Marcy, P., et al. (2020). Effect of long-acting injectable antipsychotics vs usual care on time to first hospitalization in early-phase schizophrenia: A randomized clinical trial. JAMA Psychiatry, 77, 18.
Medrano, S., Abdel-Baki, A., Stip, E., et al. (2018). Three-year naturalistic study on early use of long-acting injectable antipsychotics in first episode psychosis. Psychopharmacol Bull, 48, 2561.
Robinson, D. G., Subramaniam, A., Fearis, P. J., et al. (2019). Focused ethnographic examination of barriers to use of long-acting injectable antipsychotics. Psychiatr Serv, appips201900236.
Lindenmayer, J. P., Glick, I. D., Talreja, H., et al. (2020). Persistent barriers to the use of long-acting injectable antipsychotics for the treatment of schizophrenia. J Clin Psychopharmacol, 40, 346349.
Brain, C., Sameby, B., Allerby, K., et al. (2014). Twelve months of electronic monitoring (MEMS) in the Swedish COAST-study: A comparison of methods for the measurement of adherence in schizophrenia. Eur Neuropsychopharmacol, 24, 215222.
Velligan, D. I., Wang, M., Diamond, P., et al. (2007). Relationships among subjective and objective measures of adherence to oral antipsychotic medications. Psychiatr Serv, 58, 11871192.
Yaegashi, H., Kirino, S., Remington, G., et al. (2020). Adherence to oral antipsychotics measured by electronic adherence monitoring in schizophrenia: A systematic review and meta-analysis. CNS Drugs, 34, 579598.
Byerly, M. J., Thompson, A., Carmody, T., et al. (2007). Validity of electronically monitored medication adherence and conventional adherence measures in schizophrenia. Psychiatr Serv, 58, 844847.
Remington, G., Teo, C., Mann, S., et al. (2013). Examining levels of antipsychotic adherence to better understand nonadherence. J Clin Psychopharmacol, 33, 261263.
MacEwan, J. P., Forma, F. M., Shafrin, J., et al. (2016). Patterns of adherence to oral atypical antipsychotics among patients diagnosed with schizophrenia. J Manag Care Spec Pharm, 22, 13491361.
Lopez, V. L., Shaikh, A., Merson, J., et al. (2017). Accuracy of clinician assessments of medication status in the emergency setting – a comparison of clinician assessment of antipsychotic usage and plasma level determination. J Clin Psychopharmacol, 37, 310314.
Kurokawa, S., Kishimoto, T., Su, K.-P., et al. (2019). Psychiatrists’ perceptions of medication adherence among patients with schizophrenia: An international survey. Schizophr Res, 211, 105107.
Velligan, D. I., Lam, Y. W., Glahn, D. C., et al. (2006). Defining and assessing adherence to oral antipsychotics: A review of the literature. Schizophr Bull, 32, 724742.
Nieuwlaat, R., Wilczynski, N., Navarro, T., et al. (2014). Interventions for enhancing medication adherence. Cochrane Database Syst Rev, 2014, CD000011.
Thompson, L., Howes, C., and McCabe, R. (2016). Effect of questions used by psychiatrists on therapeutic alliance and adherence. Br J Psychiatry, 209, 4047.
McCabe, R., Healey, P. G., Priebe, S., et al. (2013). Shared understanding in psychiatrist–patient communication: Association with treatment adherence in schizophrenia. Patient Educ Couns, 93, 7379.
Sapra, M., Weiden, P. J., Schooler, N. R., et al. (2014). Reasons for adherence and nonadherence: A pilot study comparing first- and multi-episode schizophrenia patients. Clin Schizophr Relat Psychoses, 7, 199206.
Hogan, T. P., Awad, A. G., and Eastwood, R. (1983). A self-report scale predictive of drug compliance in schizophrenics: Reliability and discriminative validity. Psychol Med, 13, 177183.
Byerly, M. J., Nakonezny, P. A., and Rush, A. J. (2008). The Brief Adherence Rating Scale (BARS) validated against electronic monitoring in assessing the antipsychotic medication adherence of outpatients with schizophrenia and schizoaffective disorder. Schizophr Res, 100, 6069.
Xu, D. R., Gong, W., Gloyd, S., et al. (2018). Measuring adherence to antipsychotic medications for schizophrenia: Concordance and validity among a community sample in rural China. Schizophr Res, 201, 307314.
McEvoy, J. P., Byerly, M., Hamer, R. M., et al. (2014). Effectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: A randomized clinical trial. JAMA, 311, 19781987.
Nakonezny, P. A., Lindow, J. C., Stroup, T. S., et al. (2020). A single assessment with the Brief Adherence Rating Scale (BARS) discriminates responders to long-acting injectable antipsychotic treatment in patients with schizophrenia. Schizophr Res, 220, 9297.
Pfeiffer, P. N., Ganoczy, D., and Valenstein, M. (2008). Dosing frequency and adherence to antipsychotic medications. Psychiatr Serv, 59, 12071210.
Beebe, L. H., Smith, K., and Phillips, C. (2017). Effect of a telephone intervention on measures of psychiatric and nonpsychiatric medication adherence in outpatients with schizophrenia spectrum disorders. J Psychosoc Nurs Ment Health Serv, 55, 2936.
Xu, D. R., Xiao, S., He, H., et al. (2019). Lay health supporters aided by mobile text messaging to improve adherence, symptoms, and functioning among people with schizophrenia in a resource-poor community in rural China (LEAN): A randomized controlled trial. PLoS Med, 16, e1002785.
Uslu, E. and Buldukoglu, K. (2020). Randomized controlled trial of the effects of nursing care based on a telephone intervention for medication adherence in schizophrenia. Perspect Psychiatr Care, 56, 6371.
Gaebel, W., Riesbeck, M., von Wilmsdorff, M., et al. (2010). Drug attitude as predictor for effectiveness in first-episode schizophrenia: Results of an open randomized trial (EUFEST). Eur Neuropsychopharmacol, 20, 310316.
Quirk, A., Chaplin, R., Hamilton, S., et al. (2013). Communication about adherence to long-term antipsychotic prescribing: An observational study of psychiatric practice. Soc Psychiatry Psychiatr Epidemiol, 48, 639647.
Meyer, J. M. (2014). A rational approach to employing high plasma levels of antipsychotics for violence associated with schizophrenia: Case vignettes. CNS Spectr, 19, 432438.
Rostami-Hodjegan, A., Amin, A. M., Spencer, E. P., et al. (2004). Influence of dose, cigarette smoking, age, sex, and metabolic activity on plasma clozapine concentrations: A predictive model and nomograms to aid clozapine dose adjustment and to assess compliance in individual patients. J Clin Psychopharmacol, 24, 7078.
Meyer, J. M. (2020). Monitoring and improving antipsychotic adherence in outpatient forensic diversion programs. CNS Spectr, 25, 136144.
Müller, J., Keiser, M., Drozdzik, M., et al. (2017). Expression, regulation and function of intestinal drug transporters: An update. Biol Chem, 398, 175192.
Jönsson, A. K., Spigset, O., and Reis, M. (2019). A compilation of serum concentrations of 12 antipsychotic drugs in a therapeutic drug monitoring setting. Ther Drug Monit, 41, 348356.
Lee, J., Bies, R., Takeuchi, H., et al. (2016). Quantifying intraindividual variations in plasma clozapine levels: A population pharmacokinetic approach. J Clin Psychiatry, 77, 681687.
Ng, W., Uchida, H., Ismail, Z., et al. (2009). Clozapine exposure and the impact of smoking and gender: A population pharmacokinetic study. Ther Drug Monit, 31, 360366.
Shvartsburd, A., Sajadi, C., Morton, V., et al. (1984). Blood levels of haloperidol and thioridazine during maintenance neuroleptic treatment of schizophrenic outpatients. J Clin Psychopharmacol, 4, 194198.
Gitlin, M. J., Nuechterlein, K. H., Mintz, J., et al. (2000). Fluphenazine levels during maintenance treatment of recent-onset schizophrenia: Relation to side effects, psychosocial function and depression. Psychopharmacology, 148, 350354.
Schoretsanitis, G., Kane, J. M., Correll, C. U., et al. (2020). Blood levels to optimize antipsychotic treatment in clinical practice: A joint consensus statement of the American Society of Clinical Psychopharmacology (ASCP) and the Therapeutic Drug Monitoring (TDM) Task Force of the Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP). J Clin Psychiatry, 81, https://doi.org/10.4088/JCP.4019cs13169.
McCutcheon, R., Beck, K., Bloomfield, M. A., et al. (2015). Treatment resistant or resistant to treatment? Antipsychotic plasma levels in patients with poorly controlled psychotic symptoms. J Psychopharmacol, 29, 892897.
McCutcheon, R., Beck, K., D’Ambrosio, E., et al. (2018). Antipsychotic plasma levels in the assessment of poor treatment response in schizophrenia. Acta Psychiatr Scand, 137, 3946.
Kylleso, L., Smith, R. L., Karlstad, O., et al. (2020). Undetectable or subtherapeutic serum levels of antipsychotic drugs preceding switch to clozapine. NPJ Schizophr, 6, 17.
Roerig Division of Pfizer Inc. (2020). Geodon package insert. New York.
Beedham, C., Miceli, J. J., and Obach, R. S. (2003). Ziprasidone metabolism, aldehyde oxidase, and clinical implications. J Clin Psychopharmacol, 23, 229232.
Dalvie, D. and Di, L. (2019). Aldehyde oxidase and its role as a drug metabolizing enzyme. Pharmacol Ther, 201, 137180.
Zanger, U. M. and Schwab, M. (2013). Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther, 138, 103141.
Zanger, U. M., Klein, K., Thomas, M., et al. (2014). Genetics, epigenetics, and regulation of drug-metabolizing cytochrome p450 enzymes. Clin Pharmacol Ther, 95, 258261.
Manikandan, P. and Nagini, S. (2018). Cytochrome P450 structure, function and clinical significance: A review. Curr Drug Targets, 19, 3854.
Meyer, J. M. and Stahl, S. M. (2019). The Clozapine Handbook. Cambridge: Cambridge University Press.

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×